TD Origen Capital Fund

TD Origen Capital Fund, L.P. is a healthcare-focused venture capital fund managed by Tullis Health Investors, formerly known as Tullis-Dickerson & Co. Established in 1999, the fund operated as a Small Business Investment Company (SBIC) and focused on providing early and growth-stage capital to companies in the life sciences, biotechnology, and medical device sectors. The fund's portfolio included notable healthcare successes such as Adams Respiratory Therapeutics, the developer of the Mucinex brand, and ViaCell, a biotechnology company specializing in cord blood banking and cell therapy. Headquartered in Santa Fe, New Mexico, TD Origen Capital Fund played a significant role in financing innovative medical technologies and healthcare services. The fund was part of a larger family of investment vehicles managed by the Tullis-Dickerson team, which emphasized improving patient outcomes through strategic investments. While the fund is no longer actively making new investments, its legacy includes the successful commercialization of several widely used medical products.